Thermo Fisher Scientific (TMO) Q3 2026 earnings review
Thermo Fisher grows faster on its own, but debt stays high
Thermo Fisher's own businesses sold more than the company had planned, while its debt bill kept rising. Sales from businesses it owned a year ago rose 6%, two points above the July plan, and the drug-services division grew 15%. Chief executive Marc Casper called the quarter outstanding on both revenue and profit, and the release defers the new 2026 plan to this morning's call.
| Sales from businesses owned a year ago | +6% about 4% planned in July; 3% a year ago |
|---|---|
| Profit per share, excluding one-offs | $6.68 +15% from a year ago |
| Operating margin, excluding one-offs | 24.5% +1.2 points from a year ago |
| Full-year outlook | Update due on the call July plan: adjusted EPS $24.93–25.33 |
⚖️ Verdict: 🟢 Bullish
The story got better because the growth no longer depends on an easy comparison. A year ago the same quarter grew 3% on its own, and this one still doubled that pace while the margin widened by the amount the full-year plan needed. The bad news: adjusted profit now sits 44% above reported profit, and a new $244 million loss on a business held for sale shows more portfolio changes are coming.
The question now is whether 6% is the new pace or the top of a cycle. If the drug-services order book keeps refilling, the rate holds into 2027; if the quarter drew on work booked months ago, the fourth quarter slows toward the 2% the July plan implied. The organic rate the company sets on today's call will tell.
🐂 Bull Case
Underlying Growth Doubled Against a Harder Comparison
Thermo Fisher, the lab equipment and drug-services supplier, grows in two ways: by buying businesses and by selling more from the ones it already owns. The second kind is the test of demand, so the company reports it separately as organic growth. In July it told investors to expect about 4% of that in each second-half quarter.
Sales from businesses it owned a year ago rose 6% instead, against a quarter a year earlier that had grown 3%. Chief executive Marc Casper credited a "proven growth strategy" and called the result "outstanding financial performance on both the top and bottom line". The largest division, which makes lab supplies and manufactures and tests drugs for pharma customers, led the way.
- Laboratory Products and Biopharma Services: revenue up 15.0%, after 11.6% last quarter
- Analytical Instruments: up 5.8%, with the division's margin at 26.9%
- Life Sciences Solutions: up 5.1%, slowing from 12.6% last quarter
The stronger reading matters because the standing worry was that last quarter's 5% came from an easy comparison in instruments and a good moment in the cycle. This quarter had no easy comparison, so that worry has less support, but one strong quarter does not settle it. The question remains whether 6% is a new pace or a peak, since management still talks of 7% or more over the long term without a date.
What to watch: the fourth-quarter organic growth rate the company sets on today's call, and the actual figure in January. A rate near 6% would mean the second half of 2026 is running well above the plan management set in July.
Margins Widened by the Amount the Year Needs
Operating margin excluding one-offs reached 24.5%, up 1.2 percentage points from a year ago. Two cost lines did the work: the cost of making and delivering products fell to 57.2% of revenue from 58.2%, and selling and administrative overhead fell to 15.3% from 16.1%. Research spending held near 3% of revenue.
The size of the move matters because the full-year plan set in July promised 0.8 points of margin gain for 2026, and by our math that required about 1.2 points in the second half after only 0.4 in the first. The third quarter delivered that pace on its own, so the plan no longer leans on a fourth-quarter step the company had not yet shown.
What to watch: the fourth-quarter margin, which by our math needs to reach about 24.7% for the July plan to hold. A print at that level would mean the cost programme Thermo Fisher calls PPI is lifting profitability for a second quarter in a row, not just lapping last year's tariff costs.
Cash Flow Grew Faster Than Profit
Free cash flow, the cash left after paying for factories and equipment, reached $2.1 billion in the quarter, up 15% from a year ago. Reported net income rose only 6.5%, so the gap between what the company earns on paper and what it collects in cash moved in its favour. Cash from operations rose 14% while spending on plant and equipment grew to $437 million.
Over nine months the group has collected $4.6 billion of free cash, against $3.3 billion a year earlier. That leaves $2.3–2.8 billion to reach the $6.9–7.4 billion target set in July, by our math, and last year's fourth quarter alone produced $3.0 billion. The target therefore looks reachable without any unusual year-end collection.
What to watch: fourth-quarter free cash flow in January. A figure near last year's $3.0 billion would push the full year above the July range and give Thermo Fisher room to resume buybacks or cut debt without new borrowing.
🐻 Bear Case
Adjusted Profit Pulls Further Away From Reported Profit
Thermo Fisher reports two profit figures. The adjusted one strips out acquisition write-downs, restructuring and deal costs, and it is the one Casper used when he spoke of "outstanding financial performance on both the top and bottom line". Adjusted earnings per share rose 15% to $6.68, but the reported figure rose 9% to $4.64.
The adjusted number now sits 44% above the reported one, against 36% a year ago, by our math. The main reason is the Clario purchase: amortization of acquired intangibles rose 19% to $519 million, or 4.3% of revenue. Restructuring and other costs added $199 million, which the footnotes say includes "a held-for-sale loss" of $244 million, partly offset by a $72 million "gain on the sale of a business".
This matters because the items excluded every year are not one-offs in practice. Restructuring charges have appeared in each year of our review, and each acquisition adds more amortization, so the adjusted growth rate overstates what shareholders actually keep. A $244 million loss on a business held for sale also means another unit is leaving the group, and the release does not say which.
What to watch: the quarterly filing's note on the held-for-sale business and the fourth-quarter amortization charge. A second quarter of amortization above $500 million would mean the reported-to-adjusted gap is now a permanent feature of each quarter's results.
Debt Is Still $41 Billion After Buybacks Stopped
Thermo Fisher spent $8.9 billion on acquisitions and $4.0 billion on share buybacks in the first half, funded with new debt. The question in July was whether deleveraging would now take priority over more deals. The third quarter gave a first answer: the company bought back no shares and total borrowings fell by $1.2 billion to $41.4 billion.
Net debt, borrowings less cash and short-term investments, fell to $35.3 billion from $38.5 billion by our math, helped by $1.0 billion of proceeds from the microbiology sale. But the cost of that debt keeps rising: interest expense grew 20% to $417 million, and $2.3 billion of borrowings fall due within a year.
The pause is a positive, but one quarter of lower debt does not say whether management has changed its priorities or simply had no deal to close. Diluted shares were 371 million, down 1.9% from a year ago, so earnings per share still gets help from the earlier buybacks.
What to watch: whether the capital deployment plan on today's call includes new acquisitions or further repurchases for the fourth quarter. A plan with neither would mean the company intends to bring borrowings down further before it buys again.
Risks this quarter didn't answer
Five standing concerns got no new numbers in the press release. Each lives in the prepared remarks or the quarterly filing, so they are not yet readable rather than resolved.
- Acquired growth: deals net of the divestiture added 3 points of growth; a split between Clario and the filtration business would show whether the purchases grow as fast as the rest.
- Academic, government and China demand: no end-market commentary; a stated return to growth in either would lift the organic rate.
- Remaining performance obligations, the contracted work not yet delivered: $29.7 billion at June; a reading below that in the filing would mean the order book converts faster than it refills.
- Clinical research authorizations: the leading indicator management cites, not quantified; a stated slowdown would read on 2027.
- Tariffs and policy: no quantification; currency effect on revenue was 0% this quarter.
👓 Other Themes
Microbiology Sale Closed and Brought In $1 Billion
The company "completed our previously announced divestiture of our microbiology business" in the quarter, and the cash flow statement shows $1,021 million of proceeds. That is why Specialty Diagnostics revenue fell 6.5% to $1,098 million while its margin rose 3.6 points to 31.0%, because the unit sold earned less than the rest of the division.
Four Launches and a Mayo Clinic Data Project
New products included the Orbitrap Isora, "the first Orbitrap system designed for isotope ratio analysis", the EMPAD G2 electron detector, an FDA-cleared lupus test and a higher-capacity sequencing chip. With Mayo Clinic, Thermo Fisher launched Precure to "combine data from more than one million patient samples" using its protein-analysis tools. None has a revenue reading yet.
💲 Other KPIs
The instruments division earned more on each dollar of sales: its margin rose 4.3 points from a year ago. The division sells mass spectrometers and electron microscopes, and its margin has recovered from 20.7% in the first quarter. Revenue in the segment rose 5.8% to $2,002 million, so the gain came mostly from costs and mix.
The diagnostics division's margin rose 3.6 points from a year ago and 3.3 points from last quarter. The jump coincides with the sale of the microbiology unit, so it reflects a smaller but more profitable business rather than better pricing. Segment profit still rose to $341 million from $321 million despite the lost revenue.
Stock held for sale fell 1.8% from a year ago while revenue grew 9%, by our math. Inventories had climbed to $5,745 million in September 2025 and have held between $5.4 and $5.7 billion since. Lower stock relative to sales is one reason operating cash flow outgrew net income this quarter.
🔮 Guidance
Unchanged in the release; the company said it will update the 2026 plan on today's call. The July plan stands until then. By our math, that plan leaves fourth-quarter revenue of $12.3–13.0 billion, or about 3% growth, and adjusted EPS of $6.78–7.18, about 6% growth. After a 6% organic quarter and a 1.2-point margin gain, the July figures look conservative, and the company has raised its plan at each of the last three updates.
❓ Key Questions
Which business carries the $244 million held-for-sale loss?
The microbiology sale has closed, yet the footnotes record a new $244 million loss on a business held for sale. Investors need to know which unit is leaving, its revenue, and what the proceeds will fund.
What did Clario and filtration contribute on their own?
Deals net of the divestiture added 3 points of growth. Without standalone revenue and growth rates for the acquired businesses, nobody outside the company can test whether the purchases are growing faster than the rest.
What is remaining performance obligations at September 26?
The contracted order book stood at $29.7 billion in June. A quarter-end figure, and the amount that came with Clario, would show whether services demand is refilling the book as fast as it converts.
Does the fourth-quarter organic plan stay at 4%?
July's plan had both second-half quarters near 4%. After 6% in the third, keeping 4% for the fourth would imply a step-down management should explain, and raising it would confirm demand has improved.
Will buybacks resume now that debt has fallen?
Thermo Fisher bought no shares in the quarter and cut borrowings by $1.2 billion. The call should say whether deleveraging continues or whether the remaining $1.0 billion authorization gets used in the fourth quarter.